🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting over 82 million new cases each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Global Access

According to findings published in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves an injection and a pill. The research included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed positive views. Having a single-dose, oral treatment like this is hailed as a "game-changer" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.